Trius Therapeutics grants Bayer exclusive rights to its antibiotic torezolid phosphate in Asia-Pacific and emerging markets

Trius Therapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$249.3m on 07/29/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Bayer AG

Germany / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced